The gut microbiome and the pathogenesis of trans-arterial chemoembolization-associated liver injury
Authors:
- Jared EngelmanJEJared Engelman
- Kevin JiaKJKevin Jia
- Stephen M. RiordanStephen M. Riordan
Open Access
- 16 September 2026
- journal article
- Published by OAE Publishing Inc. in Hepatoma Research
- Vol. 12
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCCJournal of Hepatology, 2025
- Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modificationGut Microbes, 2025
- EASL Clinical Practice Guidelines on the management of hepatocellular carcinomaJournal of Hepatology, 2024
- Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategiesJournal of the Canadian Association of Gastroenterology, 2024
- Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedureLife Sciences, 2024
- Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironmentNature Communications, 2022
- The microbiota in cirrhosis and its role in hepatic decompensationJournal of Hepatology, 2021
- Rates of gut microbiome divergence in mammalsMolecular Ecology, 2017
- Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety dataHepatology, 2016
- Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosisHepatology, 2004